Jie Jiang

6PUBLICATIONS
95CO-AUTHORS
Molecular targetsBiomolecular modelling and designProteins and peptidesBiologically active molecules
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Apr 23, 2025
Acute BRCAness induction and AR pathway blockage through CDK12/7/9 degradation enhances PARP inhibitor sensitivity in prostate cancer.

Fu Gui, Baishan Jiang, Jie Jiang

|Apr 09, 2025
Antitumor Activity of Vebreltinib and Characterization of Clinicogenomic Features in Solid Tumors with MET Rearrangements.

Seshiru Nakazawa, Federica Pecci, Igor Odintsov

|Jul 01, 2024
Molecular Bidents with Two Electrophilic Warheads as a New Pharmacological Modality.

Zhengnian Li, Jie Jiang, Scott B Ficarro

|Apr 02, 2024
Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors.

Federica Pecci, Seshiru Nakazawa, Biagio Ricciuti

|Feb 01, 2024
ZNL0325, a Pyrazolopyrimidine-Based Covalent Probe, Demonstrates an Alternative Binding Mode for Kinases.

Zhengnian Li, Wenchao Lu, Tyler S Beyett

|Oct 27, 2022
Covalent disruptor of YAP-TEAD association suppresses defective Hippo signaling.

Mengyang Fan, Wenchao Lu, Jianwei Che

Pageof 1

Frequent Collaborators

3 joint publications

Tinghu Zhang

3 joint publications

Nathanael S Gray

2 joint publications

Wenchao Lu

2 joint publications

Joao V Alessi